Preventive misconception and adolescents' knowledge about HIV vaccine trials

Ott, Mary A; Alexander, Andreia B; Lally, Michelle; Steever, John B; Zimet, Gregory D
December 2013
Journal of Medical Ethics;Dec2013, Vol. 39 Issue 12, p765
Academic Journal
Objective Adolescents have had very limited access to research on biomedical prevention interventions despite high rates of HIV acquisition. One concern is that adolescents are a vulnerable population, and trials carry a possibility of harm, requiring investigators to take additional precautions. Of particular concern is preventive misconception, or the overestimation of personal protection that is afforded by enrolment in a prevention intervention trial. Methods As part of a larger study of preventive misconception in adolescent HIV vaccine trials, we interviewed 33 male and female 16-19-year-olds who have sex with men. Participants underwent a simulated HIV vaccine trial consent process, and then completed a semistructured interview about their understanding and opinions related to enrolment in a HIV vaccine trial. A grounded theory analysis looked for shared concepts, and focused on the content and process of adolescent participants' understanding of HIV vaccination and the components of preventive misconception, including experiment, placebo and randomisation. Results Across interviews, adolescents demonstrated active processing of information, in which they questioned the interviewer, verbally worked out their answers based upon information provided, and corrected themselves. We observed a wide variety of understanding of research concepts. While most understood experiment and placebo, fewer understood randomisation. All understood the need for safer sex even if they did not understand the more basic concepts. Conclusions Education about basic concepts related to clinical trials, time to absorb materials and assessment of understanding may be necessary in future biomedical prevention trials.


Related Articles

  • Older Age Is Associated with Peripheral Blood Expansion of Naïve B Cells in HIV-Infected Subjects on Antiretroviral Therapy. Van Epps, Puja; Matining, Roy M.; Tassiopoulos, Katherine; Anthony, Donald D.; Landay, Alan; Kalayjian, Robert C.; Canaday, David H. // PLoS ONE;Sep2014, Vol. 9 Issue 9, p1 

    Older HIV infected subjects were previously found to have significant B cell expansion during initial antiretroviral therapy in a prospective age-differentiated cohort of older and younger (≥45 vs. ≤30 years) HIV-infected subjects initiating antiretroviral therapy (ART) through the...

  • Immunogenicity and Safety of the Human Papillomavirus 6, 11, 16, 18 Vaccine in HIV-Infected Young Women. Kahn, Jessica A.; Xu, Jiahong; Kapogiannis, Bill G.; Rudy, Bret; Gonin, René; Liu, Nancy; Wilson, Craig M.; Worrell, Carol; Squires, Kathleen E. // Clinical Infectious Diseases;Sep2013, Vol. 57 Issue 5, p735 

    Among 16- to 23-year-old human immunodeficiency virus–infected young women who were human papillomavirus (HPV) DNA and HPV seronegative at the time of vaccination with the quadrivalent HPV vaccine, immune responses to vaccination were generally robust and the vaccine was well...

  • A Cluster Randomized Trial of Routine HIV-1 Viral Load Monitoring in Zambia: Study Design, Implementation, and Baseline Cohort Characteristics. Koethe, John R.; Westfall, Andrew O.; Luhanga, Dora K.; Clark, Gina M.; Goldman, Jason D.; Mulenga, Priscilla L.; Cantrell, Ronald A.; Chi, Benjamin H.; Zulu, Isaac; Saag, Michael S.; Stringer, Jeffrey S. A. // PLoS Clinical Trials;Mar2010, Vol. 7 Issue 3, Special section p1 

    Background:The benefit of routine HIV-1 viral load (VL) monitoring of patients on antiretroviral therapy (ART) in resource-constrained settings is uncertain because of the high costs associated with the test and the limited treatment options. We designed a cluster randomized controlled trial to...

  • HIV vaccines: education key to partial efficacy success.  // PharmaWatch: Monthly Review;Mar2005, Vol. 4 Issue 3, p31 

    The article comments on the research and development of HIV vaccines in the U.S. Researchers have investigated the novel approaches, with prime-boost vaccines, DNA vaccines and pseudovirin vaccine. It has cited that antiretroviral therapy has led to the possibility of a life expectancy...

  • When to Start Antiretroviral Therapy in Resource-Limited Settings. Rochelle P. Walensky; Lindsey L. Wolf; Robin Wood; Mariam O. Fofana; Kenneth A. Freedberg; Neil A. Martinson; A. David Paltiel; Xavier Anglaret; Milton C. Weinstein; Elena Losina // Annals of Internal Medicine;8/4/2009, Vol. 151 Issue 3, p157 

    Background: The results of international clinical trials that are assessing when to initiate antiretroviral therapy (ART) will not be available for several years. Objective: To inform HIV treatment decisions about the optimal CD4 threshold at which to initiate ART in South Africa while awaiting...

  • Seroconversion Following Nonoccupational Postexposure Prophylaxis against HIV. Roland, Michelle E.; Neilands, Torsten B.; Krone, Melissa R.; Katz, Mitchell H.; Franses, Karena; Grant, Robert M.; Busch, Michael P.; Hecht, Frederick M.; Shacklett, Barbara L.; Kahn, James O.; Bamberger, Joshua D.; Coates, Thomas J.; Chesney, Margaret A.; Martin, Jeffrey N. // Clinical Infectious Diseases;11/15/2005, Vol. 41 Issue 10, p1507 

    Background. The efficacy of antiretroviral postexposure prophylaxis (PEP) against infection with human immunodeficiency virus (HIV) following occupational exposures has prompted the use of PEP after nonoccupational exposures. There are, however, important differences between occupational and...

  • HIV Antiretroviral Postexposure Prophylaxis: A Cautionary Note. Cohen, Myron S.; Kashuba, Angela D. M.; Gay, Cynthia // Clinical Infectious Diseases;11/15/2005, Vol. 41 Issue 10, p1514 

    Presents the authors' opinions on the role of antiretroviral therapy in preventing the sexual transmission of human immunodeficiency virus (HIV) infection. Discussion on clinical trials to evaluate the efficacy of antiretroviral therapy; Views on the benefits of pre-exposure prophylaxis;...

  • Global: clinical trial shows dramatic reduction in transmission of HIV as a result of treatment. Cozac, David // HIV/AIDS Policy & Law Review;Oct2011, Vol. 15 Issue 3, p31 

    The article reports on a clinical trial conducted by the U.S. HIV Prevention Trials Network which revealed that human immunopdeficiency virus (HIV)-positive persons' adherence to an effective antiretroviral therapy reduce the risk of virus transmission by 96 percent. The trial confirmed that HIV...

  • Relationship between CD4+ Count and Non-AIDS Diseases in HIV Patients. Winslow, Dean L. // Infectious Disease Alert;Jun2008, Vol. 27 Issue 9, p101 

    EXACTLY 1397 ANTIRETROVIRAL (ARV) NAÏVE PATIENTS initiating ARVs, as part of a CPCRA-sponsored clinical trial (FIRST trial), were followed for a median of five years. Patients were randomized to one of three arms (NRTIs + PI, NRTIs + nnRTI, NRTIs + PI + nnRTI). CD4+ lymphocyte count, HIV RNA,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics